More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
New research findings could help explain the “obesity paradox,” wherein being overweight is linked to both improved outcomes in certain diseases and increased mortality rates in others.
Cannabis use is on the rise throughout the United States, but it is not as harmless as some people may believe. An in-depth analysis out of Stanford explored the many cardiovascular risks associated with regular cannabis use.
Cardiologists believe this is the first time this exact complication has been reported. Even patients who present with no known risk factors, they said, should receive regular follow-up care to ensure such incidents do not go untreated.
The patient, who was primarily eating meat, cheese and entire sticks of butter, said the yellow nodules did not hurt in any way. His cholesterol level exceeded 1000 mg/dL at the time of treatment.
This new information on the pathogenesis of both conditions could be useful for the development of interventions targeted at slowing cognitive decline.
The new Department of Imaging Sciences will be spearheaded by Elizabeth M.C. Hillman, PhD, a physicist, biomedical engineer, neuroscience researcher and inventor.
